What ЭГОЛАНЗА Treats: Main Uses and Benefits

This medication is commonly used across conditions presenting with acute episodes of mental illness where supportive symptom management is appropriate. The primary therapeutic domains include managing Schizophrenia and addressing the acute, mixed, or depressive episodes of Bipolar I Disorder.

The treatment helps address symptom clusters that may become intense or disruptive, such as hallucinations, delusions, and severe manic agitation. It is applied in clinical settings that involve acute or unstable symptom patterns and is commonly used when short-term symptomatic assistance is needed. It contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. The treatment is considered relevant for easing challenging symptomatic phases and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Disruptive Symptoms

• ЭГОЛАНЗА is relevant for managing symptoms that interfere with daily comfort and is commonly used when short-term symptomatic assistance is needed for conditions involving episodic manifestations.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use ЭГОЛАНЗА

Official regulatory documents define strict criteria for who is eligible to use ЭГОЛАНЗА (Olanzapine) based on age, comorbidity, and physiological status.

---

Classification	Official Statement (As per Label)
Contraindications	Use is strictly prohibited in patients with known hypersensitivity to olanzapine or any formulation component, and in patients with known risk of narrow-angle glaucoma [1.1, 1.2]. The Orally Disintegrating Tablet (ODT) form is contraindicated in patients with Phenylketonuria (PKU) [1.2].
Absolute Exclusion	The medicine is not approved for elderly patients with dementia-related psychosis due to a significantly increased risk of death and cerebrovascular adverse events [1.1, 3.1].
Age-Group Approval	Monotherapy is approved for adults and adolescents ge 13 years of age. Combination use with fluoxetine is approved for patients ge 10 years [1.1, 2.2]. The EMA generally does not recommend use in patients under 18 due to limited long-term safety data [1.2].
Conditional Use	A lower starting dose (5 mg) should be considered for geriatric patients, patients with moderate hepatic impairment (Child-Pugh Class A or B), and those with renal impairment [1.2, 4.3]. Caution is advised for patients with conditions predisposing to hypotension [1.4].
Pregnancy Status	Exposure during the third trimester may result in extrapyramidal or withdrawal symptoms in the neonate, necessitating a careful benefit-risk evaluation [1.1].

---

Official regulatory documents define eligibility through absolute prohibitions, strong non-approvals for high-risk groups, and conditional requirements based on a patient’s age or compromised organ function. This established structure dictates the specific population boundaries for the use of ЭГОЛАНЗА.

Interactions with other medicines and products

Interactions with ЭГОЛАНЗА (Olanzapine) are primarily categorized by their effect on drug exposure and the potential for additive pharmacodynamic consequences, as detailed in regulatory documents.

Exposure Modification

The most significant pharmacokinetic interactions are mediated by the CYP1A2 enzyme. Co-administration with known inducers of CYP1A2, such as Carbamazepine and Smoking (Tobacco), increases olanzapine clearance, leading to reduced plasma concentrations. Conversely, co-administration with strong inhibitors of CYP1A2, such as Fluvoxamine, may significantly inhibit olanzapine metabolism, resulting in increased exposure, with documented AUC increases exceeding 100% in some cases. Activated Charcoal can reduce the bioavailability of oral olanzapine by 50% to 60%, requiring a separation of administration by at least two hours.

Pharmacodynamic and Administration Restrictions

Additive effects occur with other central nervous system (CNS) depressants, including Alcohol and other centrally acting medicines, which may potentiate sedation and orthostatic hypotension. The FDA recommends against the concomitant use of intramuscular olanzapine with parenteral benzodiazepines due to the risk of excessive sedation. Furthermore, the injectable form must not be combined in a syringe with certain other solutions (e.g., Diazepam injection) due to physical incompatibility. A specific population-based caution restricts the use with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia.

ЭГОЛАНЗА (Olanzapine) functions as a multi-receptor antagonist primarily in the central nervous system. Its main molecular targets include Dopamine receptors (D1 through D4) and Serotonin receptors (5-HT2A, 5-HT2C, 5-HT3, and 5-HT6). The drug exhibits a high binding affinity for the 5-HT2A and D2 receptors, occupying and inhibiting their activity.

Antagonism of the D2 receptors within the mesolimbic pathway modulates dopaminergic neurotransmission. Simultaneous antagonism of the 5-HT2A receptors, particularly in the frontal cortex, contributes to the overall modulation of neurochemical signaling. ЭГОЛАНЗА also acts as an antagonist at Histamine H1, alpha-1 adrenergic, and Muscarinic M1-M5 receptors, contributing to its broader pharmacological profile.

Downstream, this complex blockade of multiple G protein-coupled receptors leads to modifications in intracellular signaling cascades, ultimately regulating the balance of neurotransmitter activity in various brain regions. The systemic physiological consequence is a broad-spectrum neuromodulation of key monoamine pathways.

Official Administration Guidelines

ЭГОЛАНЗА (Olanzapine) is administered through distinct official routes based on the required speed of action and clinical context. The primary administration method is oral, available as conventional tablets and Orally Disintegrating Tablets (ODT). The medication is typically taken once daily, and the oral form can be administered without regard to meals. The ODT form provides an alternative intake method, designed to dissolve quickly on the tongue or to be mixed in a small volume of water.

For oral treatment of conditions like schizophrenia, the official starting dose is generally 5 mg to 10 mg once daily. The maximum recommended daily dose for oral use is 20 mg. Any dose changes for maintenance therapy must occur at intervals of not less than one week. A lower initial dose of 5 mg should be considered for specific populations, including older adults and patients with known hepatic or renal impairment.

For the rapid control of acute agitation, a short-acting, 10 mg intramuscular (IM) injection is available. This route is strictly for injection into a muscle and must not be administered intravenously. Subsequent IM injections, if necessary, are governed by strict time intervals (e.g., 2 hours or 4 hours minimum spacing) and a defined 24 hour maximum limit.

Research evidence / Overview of studies for ЭГОЛАНЗА

The research evidence for ЭГОЛАНЗА (Olanzapine) is drawn from authoritative sources, including the findings of Randomized Controlled Trials (RCTs), systematic reviews, and long-term studies. This overview describes the type of evidence that exists for each clinical situation and the high-level outcomes that researchers monitored, without offering clinical guidance or making claims about individual results.

---

Evidence for Use in Schizophrenia

The clinical evaluation for this condition was developed through multiple short-term, randomized controlled trials (RCTs) that compared the medicine to a placebo (an inactive substance) or to other active treatments. These studies were used in research exploring how symptoms change over time and monitored changes in psychiatric symptom severity using validated instruments. Researchers also tracked patients’ global clinical status and explored longer-term outcomes like the frequency of symptoms returning in maintenance trials. The populations studied included both adults and adolescents (ages 13–17).

Acute trials, typically lasting six weeks or longer, reported measurements of change in symptom scale scores. Long-term studies tracked patient retention in treatment and monitored the time elapsed before symptoms were observed again over follow-up periods that extended up to one year.

The research consistently notes that the medicine was associated with specific changes in metabolic markers (e.g., blood sugar or weight), which is a factor monitored in long-term continuation studies. Certainty remains low regarding the long-term consistency of observed patterns in relation to other therapeutic options.

---

Evidence for Use in Bipolar I Disorder (Manic and Mixed Episodes)

Evidence was derived from short-term, placebo-controlled RCTs that were relevant in trials assessing short-term or episodic symptom patterns. Researchers primarily tracked changes in manic symptom severity (e.g., YMRS scores), global clinical status, and the time elapsed before the recurrence of mood episodes in long-term designs. Populations included adults and adolescents (ages 13–17).

There is limited information for long-term outcomes when comparing the observed patterns against other established mood stabilizers. The same metabolic patterns observed in schizophrenia research was associated with changes that are tracked in adherence studies.

---

What is Still Uncertain About ЭГОЛАНЗА

The research describes several areas where certainty remains low:

• Long-Term Impact: The long-term effects on metabolic and cardiovascular health are not fully established over treatment durations longer than one year.
• Monotherapy for Depression: Comparative evidence is lacking for ЭГОЛАНЗА as a stand-alone medicine for Bipolar I depressive episodes, as the evidence is specific to the combination treatment with fluoxetine.
• Evidence Quality: Although the amount of core evidence is large, the interpretation of some adolescent study results has been described as mixed due to variations in statistical methodology.

Key Studies & References

1. NIH MedlinePlus Drug Information: Olanzapine (For core indications and patient context)
2. Olanzapine. StatPearls [Internet] (For pharmacological class and chemical context)
3. Olanzapine for acute mood episodes in bipolar disorder: a systematic review and meta-analysis (For Bipolar I Mania/Mixed acute evidence)

Common questions about ЭГОЛАНЗА (FAQ)

---

Q: How quickly should I expect to feel the effects of ЭГОЛАНЗА?

Official product information shows that the medicine is absorbed relatively quickly. For the oral tablet, the highest concentration of the drug in the bloodstream typically occurs around 6 hours after the dose is taken. If the medication is given as an intramuscular injection for agitation, the peak concentration is achieved much faster, usually within 15 to 45 minutes.

---

Q: Can ЭГОЛАНЗА affect my energy levels during the day?

Yes, official safety information indicates that somnolence (sleepiness or drowsiness) is a very common side effect reported by patients. This feeling of sedation or low energy is related to how the drug works on chemical messengers in the brain.

---

Q: How long does the effect of one dose of ЭГОЛАНЗА typically last?

The fact that it is typically prescribed to be taken once daily suggests a prolonged effect. Pharmacokinetic studies show the average half-life of the drug in the body is approximately 30 hours, though it can vary between individuals. The half-life refers to the time it takes for half of the drug to be eliminated from the bloodstream.

---

Q: Is ЭГОЛАНЗА generally safe for older adults?

Safety information requires caution for older adults. Regulatory documents carry a boxed warning that the medicine is not approved for use in elderly patients with dementia-related psychosis due to an increased risk of death and serious cerebrovascular events. For other older adults, official guidelines recommend considering a lower starting dose.

---

Q: What happens if I forget to take my ЭГОЛАНЗА dose?

Official medication information addresses missed doses. It typically advises taking a missed dose as soon as it is remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped. Taking two doses together is advised against.

---

Q: Is there a risk of becoming dependent on ЭГОЛАНЗА?

The official product label does not specifically use the term 'dependence.' However, regulatory documents strongly caution that the medication should not be stopped suddenly. The warning is to prevent potential withdrawal symptoms or severe side effects, and discontinuation requires a gradual reduction under medical supervision.

---

Q: Why do doctors prescribe ЭГОЛАНЗА for conditions other than schizophrenia?

According to the official indications, the medicine is also approved to treat the manic or mixed episodes associated with Bipolar I Disorder. Furthermore, it is approved for use in combination with another medicine (fluoxetine) for depressive episodes associated with Bipolar I Disorder and for treatment-resistant depression.

---

Q: What should I tell my doctor if I experience dizziness on ЭГОЛАНЗА?

Dizziness is listed as a common side effect and can be related to orthostatic hypotension (a drop in blood pressure when moving from sitting or lying down to standing). Regulatory warnings advise that this risk is greatest during the initial stages of treatment. Patients are advised to discuss all instances of dizziness with their healthcare provider.

---

Q: Is it necessary to have regular blood tests while taking ЭГОЛАНЗА?

Yes, official safety documents recommend that patients receive periodic monitoring. Due to the risk of metabolic changes, the need for blood tests for fasting blood glucose and fasting blood lipids is a part of the mandatory monitoring regimen.

---

Q: Why is rapid discontinuation of ЭГОЛАНЗА generally advised against?

Rapid discontinuation is advised against because it can lead to the occurrence of serious side effects or withdrawal symptoms. If discontinuation is necessary, the official guidance recommends that the dosage be reduced gradually under the supervision of a healthcare professional.

---

Q: Can I drive or operate machinery while taking ЭГОЛАНЗА?

The medicine has the potential to impair motor skills, judgment, and thinking, which is a key safety warning. Patients are officially cautioned to use care when performing hazardous tasks, such as driving an automobile or operating heavy machinery, until they know how the medicine affects them.

---

Q: Why is close monitoring by a doctor needed when starting ЭГОЛАНЗА?

Close monitoring is required primarily to manage the risk of initial side effects and to establish a metabolic baseline. This includes checking for orthostatic hypotension during initial dose adjustments and collecting baseline levels for metabolic factors like blood glucose and lipids.

---

Q: Is ЭГОЛАНЗА safe to use during pregnancy or while breastfeeding (in general terms)?

Official labeling states that exposure during the third trimester of pregnancy may result in withdrawal or extrapyramidal symptoms in the newborn. For breastfeeding, the product label indicates that the drug is present in breast milk, and the decision to breastfeed must consider the benefit-risk ratio for the infant and the mother.

---

Q: Why do some people refer to ЭГОЛАНЗА as a 'mood stabilizer'?

Although ЭГОЛАНЗА is classified as an Atypical Antipsychotic, it is officially approved for the treatment of manic and mixed episodes associated with Bipolar I Disorder. Because of this use in treating bipolar disorder, which involves mood dysregulation, it is sometimes functionally referred to as a 'mood stabilizer' in common discussions.

---

Q: Can ЭГОЛАНЗА interact with common over-the-counter pain relievers?

While the single-ingredient label does not list direct interactions with common pain relievers, the product labeling for the combination of olanzapine with fluoxetine notes a potential concern. This combination, when used with certain over-the-counter pain relievers such as NSAIDs (like ibuprofen) or aspirin, may increase the risk of bleeding.

---

Q: What should I do if my side effects from ЭГОЛАНЗА feel too strong?

Regulatory warnings highlight the importance of recognizing signs of rare but serious reactions, such as a severe rash or fever. For any severe or serious symptoms (such as DRESS or NMS), seeking immediate medical attention is advised. Patients should discuss all side effect concerns with a healthcare professional.

---

Q: Is it possible for ЭГОЛАНЗА to cause a skin rash?

Yes, a skin rash is a potential risk. The medicine carries a warning for DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), a rare but serious, potentially life-threatening allergic reaction. DRESS can initially appear as a rash, often accompanied by fever and swollen glands.

---

Q: Does the time of day I take ЭГОЛАНЗА matter for its effectiveness?

The medicine is generally administered only once daily, and the effectiveness is not dependent on taking it with food. Because a common side effect is somnolence (sleepiness), some prescribers suggest taking the daily dose in the evening to help manage daytime drowsiness.

Storage and Disposal of ЭГОЛАНЗА (Olanzapine)

The storage and disposal of Olanzapine must strictly adhere to regulatory guidelines to ensure product integrity and safety.

---

Storage Conditions

Requirement	Specifics
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Must be protected from light and moisture (kept dry).
Packaging	Store in the original container/package. Orally disintegrating tablets (ODTs) must be handled with dry hands when removed for immediate use.
Safety	Keep the medication out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Olanzapine must not be thrown into household trash or wastewater. The product must be disposed of according to local pharmaceutical waste regulations or returned to a pharmacist or authorized collection site. Do not use the medication after the expiration date printed on the package.